Treatment with a combination of both an anti-PD-1 and an anti-CTLA-4 antibody after exposure to lurbinectedin significantly extended the survival in murine models when compared with single ICI therapies; moreover, tumor-free mice that were rechallenged with the same cancer type show tumor rejection, indicating that the combination of lurbinectedin and immunotherapy may generate immunological memory (23). Here, CTLA4 is linked to neoplasm.